Comparison of the Improvement and Safety of the Ankle Brachial Arterial Pressure Index of Sarpogr… (NCT06424548) | Clinical Trial Compass
Not Yet RecruitingNot Applicable
Comparison of the Improvement and Safety of the Ankle Brachial Arterial Pressure Index of Sarpogrelate and Clopidogrel in Stroke Patients With Decreased Ankle Brachial Arterial Pressure Index and Intermittent Claudication of Lower Limb Vascular Atherosclerosis.
100 participantsStarted 2024-05-16
Plain-language summary
The clinical trial aims to confirm the improvement effect of the ankle brachial index and the safety of sarpogrelate administration compared to clopidogrel in stroke patients with decreased ankle brachial arterial pressure index and intermittent claudication of lower limb vascular atherosclerosis. Subjects are assigned to one of the two combinations through random allocation.
Intervention group: Aspirin 100mg + sarpogrelate 300mg dosing group, Control group: Aspirin 100mg + clopidogrel 75mg dosing group. This clinical trial is a prospective open study and will be conducted in compliance with the usual diagnosis and treatment process, and in particular, all trial subjects will be tested and treated appropriately in accordance with the standard treatment guidelines for ischemic stroke during the clinical trial period.
Who can participate
Age range19 Years
SexALL
See this in plain English?
AI-rewrites the medical criteria so a patient or caregiver can understand them. Always confirm with the trial site.
Inclusion criteria
✓. Aged 19 or over.
✓. Neurologically stable patients after 7 days and within 6 months of diagnosis of ischemic stroke.
✓. Patients with ankle-brachial index (ABI) \<0.9 performed within 6 months of screening, with lower limb vascular stenosis and intermittent claudication.
✓. A person who voluntarily agrees to participate in this clinical trial in writing.
Exclusion criteria
✕. Patients who are unable or contraindicated to administer antithrombotic drugs.
✕. Patients with less than 80,000 platelets, less than 8.0 hemoglobin, liver levels and total bilirubin levels three times normal according to laboratory standards, according to blood tests conducted within one month.
✕. Patients identified as undergoing renal replacement therapy such as dialysis due to acute or terminal nephropathy during screening.
✕. Patients diagnosed with or treated for cancer within 6 months of screening, or identified as having recurrent or metastatic cancer.